Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials
Jupiter Neurosciences (NASDAQ: JUNS) announced a strategic focus on targeting the NLRP3 inflammasome in upcoming clinical trials of their JOTROL™ platform. This shift aims to enhance treatments for neurodegenerative diseases, longevity, and aging. The NLRP3 inflammasome is linked to CNS disorders, metabolic diseases, and aging-related conditions. JOTROL overcomes resveratrol’s issues of poor bioavailability and gastrointestinal side effects, reaching therapeutic plasma levels and crossing the blood-brain barrier.
CEO Christer Rosén emphasized JOTROL’s potential for diseases like Parkinson’s and Alzheimer’s, with preclinical studies showing positive results for Parkinson’s at the University of Miami. The company is refining its Alzheimer’s strategy, leveraging a prior Phase I study. The recent U.S. Senate's
Jupiter Neurosciences (NASDAQ: JUNS) ha annunciato un focus strategico sul mirare all'inflammasoma NLRP3 nei prossimi studi clinici della loro piattaforma JOTROL™. Questo cambiamento ha come obiettivo quello di migliorare i trattamenti per le malattie neurodegenerative, la longevità e l'invecchiamento. L'inflammasoma NLRP3 è collegato a disordini del sistema nervoso centrale, malattie metaboliche e condizioni legate all'invecchiamento. JOTROL supera i problemi di scarsa biodisponibilità e effetti collaterali gastrointestinali del resveratrolo, raggiungendo livelli terapeutici nel plasma e attraversando la barriera ematoencefalica.
Il CEO Christer Rosén ha sottolineato il potenziale di JOTROL per malattie come il Morbo di Parkinson e l'Alzheimer, con studi preclinici che mostrano risultati positivi per il Parkinson presso l'Università di Miami. L'azienda sta perfezionando la sua strategia per l'Alzheimer, sfruttando uno studio precedente di Fase I. Il recente intervento del Senato degli Stati Uniti è stato...
Jupiter Neurosciences (NASDAQ: JUNS) anunció un enfoque estratégico en la orientación hacia el inflammasoma NLRP3 en los próximos ensayos clínicos de su plataforma JOTROL™. Este cambio tiene como objetivo mejorar los tratamientos para enfermedades neurodegenerativas, longevidad y envejecimiento. El inflammasoma NLRP3 está relacionado con trastornos del sistema nervioso central, enfermedades metabólicas y condiciones relacionadas con el envejecimiento. JOTROL supera los problemas de baja biodisponibilidad y efectos secundarios gastrointestinales del resveratrol, alcanzando niveles terapéuticos en plasma y atravesando la barrera hematoencefálica.
El CEO Christer Rosén enfatizó el potencial de JOTROL para enfermedades como Parkinson y Alzheimer, con estudios preclínicos que muestran resultados positivos para Parkinson en la Universidad de Miami. La compañía está refinando su estrategia para el Alzheimer, aprovechando un estudio previo de Fase I. El reciente pronunciamiento del Senado de EE.UU. fue...
Jupiter Neurosciences (NASDAQ: JUNS)는 다가오는 임상 시험에서 NLRP3 인플라마좀을 대상으로 하는 전략적 접근을 발표했습니다. 이 변화는 신경퇴행성 질환, 장수 및 노화에 대한 치료를 향상시키는 것을 목표로 합니다. NLRP3 인플라마좀은 중추신경계 장애, 신진대사 질환 및 노화 관련 질환과 관련이 있습니다. JOTROL은 레스베라트롤의 낮은 생체이용률과 위장관 부작용 문제를 극복하여 치료적인 혈장 수준에 도달하고 혈액-뇌 장벽을 넘습니다.
CEO 크리스터 로센은 JOTROL의 파킨슨병 및 알츠하이머병에 대한 잠재력을 강조하며, 마이애미 대학교에서 파킨슨병에 대한 긍정적인 결과를 보여주는 전임상 연구 결과를 발표했습니다. 회사는 이전 1상 연구를 활용하여 알츠하이머 전략을 다듬고 있습니다. 최근 미국 상원의 개입은...
Jupiter Neurosciences (NASDAQ: JUNS) a annoncé un axe stratégique visant à cibler l'inflammasome NLRP3 dans les prochains essais cliniques de leur plateforme JOTROL™. Ce changement vise à améliorer les traitements pour les maladies neurodégénératives, la longévité et le vieillissement. L'inflammasome NLRP3 est lié à des troubles du système nerveux central, des maladies métaboliques et des conditions liées au vieillissement. JOTROL surmonte les problèmes de faible biodisponibilité et d'effets secondaires gastro-intestinaux du resvératrol, atteignant des niveaux plasmatiques thérapeutiques et traversant la barrière hémato-encéphalique.
Le PDG Christer Rosén a souligné le potentiel de JOTROL pour des maladies comme le Parkinson et Alzheimer, avec des études précliniques montrant des résultats positifs pour le Parkinson à l'Université de Miami. L'entreprise affine sa stratégie pour l'Alzheimer en s'appuyant sur une étude précédente de phase I. Le récent discours du Sénat américain était...
Jupiter Neurosciences (NASDAQ: JUNS) hat einen strategischen Fokus auf die Zielsetzung des NLRP3-Inflammasoms in den bevorstehenden klinischen Studien ihrer Plattform JOTROL™ angekündigt. Dieser Wandel zielt darauf ab, die Behandlungen für neurodegenerative Erkrankungen, Langlebigkeit und Alterung zu verbessern. Das NLRP3-Inflammasom steht im Zusammenhang mit Erkrankungen des zentralen Nervensystems, metabolischen Erkrankungen und altersbedingten Zuständen. JOTROL überwindet die Probleme der schlechten Bioverfügbarkeit und gastrointestinalen Nebenwirkungen von Resveratrol und erreicht therapeutische Plasmaspiegel, während es die Blut-Hirn-Schranke überquert.
CEO Christer Rosén betonte das Potenzial von JOTROL für Krankheiten wie Parkinson und Alzheimer, wobei präklinische Studien an der University of Miami positive Ergebnisse für Parkinson zeigen. Das Unternehmen verfeinert seine Strategie für Alzheimer, indem es eine frühere Phase-I-Studie nutzt. Die jüngste Äußerung des US-Senats war...
- None.
- None.
Jupiter, Florida, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced a strategic focus on targeting the NLRP3 inflammasome in all upcoming clinical trials. This shift aims to unlock new therapeutic potential for neurodegenerative diseases, longevity, and aging, positioning the Company at the forefront of innovation in neuroinflammation treatments.
The NLRP3 inflammasome is a key inflammation driver linked to central nervous system (CNS) disorders, metabolic diseases, and aging-related conditions. JOTROL, Jupiter’s flagship product, overcomes resveratrol’s historical challenges of poor bioavailability and gastrointestinal side effects. With its ability to safely reach therapeutic levels in plasma and cross the blood-brain barrier, JOTROL represents a groundbreaking advance for targeting neuroinflammatory pathways like NLRP3.
“By adding focus on NLRP3 evaluation, in addition to earlier established biomarkers, we expect to maximize JOTROL’s therapeutic potential in addressing unmet medical needs,” said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. “We believe JOTROL’s ability to inhibit NLRP3, based on multiple published resveratrol trials, makes it an ideal candidate for diseases such as Parkinson’s and Alzheimer’s, and it positions Jupiter to pursue additional collaborations, particularly in the rapidly growing obesity treatment market.”
Advancing Parkinson’s and Alzheimer’s Research
Preclinical studies at the University of Miami have demonstrated JOTROL’s ability to mitigate key biomarkers of Parkinson’s disease, making this a primary target for Jupiter’s future trials. The company also continues to refine its strategy for Alzheimer’s research, leveraging its prior Phase I pharmacokinetics study funded by the National Institute on Aging.
The U.S. Senate’s recent passage of the "National Plan to End Parkinson’s Act" highlights the growing urgency for effective treatments, and Jupiter is aligning its clinical focus to capitalize on this momentum. With a
Market Expansion and Strategic Partnerships
In addition to its CNS focus, Jupiter is evaluating opportunities in longevity and metabolic health. Emerging data suggests that JOTROL’s inhibition of NLRP3, when combined with GLP-1 treatments, could enhance weight loss outcomes, opening doors to potential collaborations in the obesity market—a multibillion-dollar industry.
The Company is also pursuing expansion in the Asia-Pacific region, driven by strong interest from regional partners. Recent agreements to accelerate clinical development and regulatory approval underscore Jupiter’s commitment to global growth.
Why JOTROL is Different
JOTROL’s patented micellar delivery system allows resveratrol to reach effective concentrations in the bloodstream without causing gastrointestinal side effects—a longstanding barrier for resveratrol-based treatments. This innovative approach has been validated in peer-reviewed studies and forms the basis of Jupiter’s strategy to pursue regulatory approval across multiple indications.
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company’s platform product, JOTROL™, is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company’s pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer’s Disease, Parkinson’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com.
About JOTROL
Resveratrol is one of the world’s most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication.\
Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer’s Disease trial, and Yui et al., Friedreich’s Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL trials, were published in the Journal of Alzheimer’s Disease and AAPS Open in February 2022.
About NLRP3
The NLRP3 inflammasome is a critical component of the innate immune system that mediates caspase-1 activation and the secretion of proinflammatory cytokines IL-1β/IL-18 in response to microbial infection and cellular damage. However, the aberrant activation of the NLRP3 inflammasome has been linked with several inflammatory disorders, which include cryopyrin-associated periodic syndromes, Alzheimer’s disease, diabetes, and atherosclerosis. The NLRP3 inflammasome is activated by diverse stimuli, and multiple molecular and cellular events, including ionic flux, mitochondrial dysfunction, and the production of reactive oxygen species, and lysosomal damage have been shown to trigger its activation. Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. Int J Mol Sci. 2019 Jul 6;20(13):3328. doi: 10.3390/ijms20133328. PMID: 31284572; PMCID: PMC6651423.
FORWARD-LOOKING STATEMENTS
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations, including the use of proceeds from the Offering. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
1-800-RED-CHIP (733-2447)
JUNS@redchip.com
